RPG Life Sciences Q1 FY27 Results: Revenue ₹19,985 Lakhs, Profit ₹3,057 Lakhs
RPG Life Sciences reported unaudited financial results for Q1 FY27. Standalone revenue was ₹19,985 lakhs, with a profit of ₹3,057 lakhs. Consolidated revenue was ₹20,039 lakhs, with a profit of ₹3,076 lakhs. EPS stood at ₹18.49 (standalone) and ₹18.60 (consolidated). The Board also approved the transfer of the API division to a subsidiary.
The announcement includes the financial results for the quarter, which are material information for investors. Additionally, the approval for the transfer of the API division is a significant corporate action that could impact the company's structure.
The announcement reports financial results and a corporate action. While the results appear stable, there are no significant positive or negative triggers mentioned that would warrant a strong sentiment.
RPG Life Sciences Limited announced its unaudited financial results for the quarter ended June 30, 2026. The company's Board of Directors, in a meeting held on July 28, 2026, approved the standalone and consolidated financial results.
The total income for the quarter stood at ₹19,985 lakhs (standalone) and ₹20,039 lakhs (consolidated). Expenses amounted to ₹4,121 lakhs (standalone) and ₹4,649 lakhs (consolidated).
Profit before exceptional items and tax was ₹15,864 lakhs (standalone) and ₹15,893 lakhs (consolidated). After accounting for exceptional items and taxes, the profit for the period was ₹3,057 lakhs (standalone) and ₹3,076 lakhs (consolidated).
Earnings per share for the quarter were ₹18.49 (standalone) and ₹18.60 (consolidated).
The company also reported that the Board of Directors had approved the transfer of the API division to its wholly-owned subsidiary, RPG Active Pharma Limited, which was incorporated on December 24, 2025. This transaction is subject to requisite approvals and customary conditions precedent.
What to do with a filing like this
RPG Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by RPG Life Sciences Limited. Read the original for the full detail.